{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:11:29Z","timestamp":1791972689131,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,6]]},"DOI":"10.7759\/cureus.87389","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T01:13:39Z","timestamp":1751850819000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparative Efficacy and Toxicity of Modified FOLFIRINOX and Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma: A Real-World Retrospective Analysis"],"prefix":"10.7759","author":[{"given":"Arpit","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyajeet","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedita","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akanksha","family":"Jaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaifali","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmishtha  A","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Talwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy T","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al.. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011, 364:1817-25. 10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff DD","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al.. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013, 369:1691-703. 10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4869","article-title":"Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial","volume":"31","author":"Gourgou-Bourgade S","year":"2013","unstructured":"Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al.. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial. J Clin Oncol. 2013, 31:23-9. 10.1200\/JCO.2012.44.4869","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2017.02.02","article-title":"Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer","volume":"8","author":"Muranaka T","year":"2017","unstructured":"Muranaka T, Kuwatani M, Komatsu Y, et al.. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol. 2017, 8:566-71. 10.21037\/jgo.2017.02.02","journal-title":"J Gastrointest Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.328","article-title":"Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort","volume":"113","author":"Portal A","year":"2015","unstructured":"Portal A, Pernot S, Tougeron D, et al.. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015, 113:989-95. 10.1038\/bjc.2015.328","journal-title":"Br J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9636","article-title":"Metastatic pancreatic cancer: ASCO clinical practice guideline update","volume":"36","author":"Sohal DP","year":"2018","unstructured":"Sohal DP, Kennedy EB, Khorana A, et al.. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018, 36:2545-56. 10.1200\/JCO.2018.78.9636","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI- 1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam A","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, et al.. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI- 1): a global, randomised, open-label, phase 3 trial. Lancet. 2016, 387:545-57. 10.1016\/S0140-6736(15)00986-1","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.09.015","article-title":"Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)","volume":"50","author":"Trouilloud I","year":"2014","unstructured":"Trouilloud I, Dupont-Gossard AC, Malka D, et al.. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM). Eur J Cancer. 2014, 50:3116-24. 10.1016\/j.ejca.2014.09.015","journal-title":"Eur J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker M","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, et al.. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016, 17:801-10. 10.1016\/S1470-2045(16)00172-8","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0131","article-title":"Pancreatic adenocarcinoma, version 2.2017, NCCN guidelines","volume":"15","author":"Tempero MA","year":"2017","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, et al.. Pancreatic adenocarcinoma, version 2.2017, NCCN guidelines. J Natl Compr Canc Netw. 2017, 15:1028-61. 10.6004\/jnccn.2017.0131","journal-title":"J Natl Compr Canc Netw"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071338","article-title":"Pancreatic ductal adenocarcinoma: current and evolving therapies","volume":"18","author":"Adamska A","year":"2017","unstructured":"Adamska A, Domenichini A, Falasca M. Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci. 2017, 18:10.3390\/ijms18071338","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-015-9724-1","article-title":"A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs","volume":"46","author":"Carrato A","year":"2015","unstructured":"Carrato A, Falcone A, Ducreux M, et al.. A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs. J Gastrointest Cancer. 2015, 46:201-11. 10.1007\/s12029-015-9724-1","journal-title":"J Gastrointest Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08237-2","article-title":"Response and outcomes after neoadjuvant therapy for borderline resectable pancreatic cancer: does histologic subtype matter?","volume":"27","author":"Perri G","year":"2020","unstructured":"Perri G, Prakash L, Qiao W, et al.. Response and outcomes after neoadjuvant therapy for borderline resectable pancreatic cancer: does histologic subtype matter?. Ann Surg Oncol. 2020, 27:2283-91. 10.1245\/s10434-020-08237-2","journal-title":"Ann Surg Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02751","article-title":"Randomized phase II study of gemcitabine and nab-paclitaxel with or without cisplatin in patients with newly diagnosed metastatic pancreatic cancer","volume":"38","author":"O'Reilly EM","year":"2020","unstructured":"O'Reilly EM, Lee JW, Zalupski M, et al.. Randomized phase II study of gemcitabine and nab-paclitaxel with or without cisplatin in patients with newly diagnosed metastatic pancreatic cancer. J Clin Oncol. 2020, 38:1895-904. 10.1200\/JCO.19.02751","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi JD","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020, 395:2008-20. 10.1016\/S0140-6736(20)30974-0","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/380892-comparative-efficacy-and-toxicity-of-modified-folfirinox-and-gemcitabine-plus-nab-paclitaxel-in-advanced-pancreatic-ductal-adenocarcinoma-a-real-world-retrospective-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T01:13:40Z","timestamp":1751850820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/380892-comparative-efficacy-and-toxicity-of-modified-folfirinox-and-gemcitabine-plus-nab-paclitaxel-in-advanced-pancreatic-ductal-adenocarcinoma-a-real-world-retrospective-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,6]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.87389","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,6]]}}}